Interleukin-6 blocking agents for treating COVID-19: a living systematic review

Ghosn, Lina; Chaimani, Anna; Evrenoglou, Theodoros; Davidson, Mauricia; Graña, Carolina; Schmucker, Christine; Bollig, Claudia; Henschke, Nicholas; Sguassero, Yanina; Hansen Nejstgaard, Camilla; Menon, Sonia; Van Nguyen, Thu; Ferrand, Gabriel; Kapp, Philipp; Riveros, Carolina; Ávila, Camila; Devane, Declan; J Meerpohl, Joerg; Rada, Gabriel; Hróbjartsson, Asbjørn; Grasselli, Giacomo; Tovey, David; Ravaud, Philippe; Boutron, Isabelle

doi:10.1002/14651858.cd013881

Public

Interleukin-6 blocking agents for treating COVID-19: a living systematic review

Published in Cochrane Database of Systematic Reviews • Mar 18, 2021

Authors:

Lina Ghosn

Anna Chaimani

Theodoros Evrenoglou

Abstract

BACKGROUND: Interleukin 6 (IL-6) blocking agents have been used for treating severe coronavirus disease 2019 (COVID-19). Their immunosuppressive effect might be valuable in patients with COVID-19 characterised by substantial immune system dysfunction by controlling inflammation and promoting disease...

Subject

Medicine

Placebo

Clinical trial

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!